Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.


The family-owned group, which has 85 pharmacies across England, has installed the FLOWRx Auto Hub in its new warehouse in Uckfield, Sussex.

Its pharmacies will use the FLOWRx InStore software to ensure their pharmacy spokes have full visibility of every prescription dispensed offsite and its status.

Once orders are received back in branch, FLOWRx InStore will also guide pharmacy teams through the dispensing process for any items that could not be dispensed by the hub.

Dave Howells, deputy chief operations officer for Kamsons, explained that whilst the new pharmacy contract puts even greater emphasis on the requirement for pharmacies to deliver more clinically-led services, dispensing remains ‘core’ to what pharmacies do.

“We knew that moving to a hub and spoke model was one of the ways that we could release capacity in branch to create more time to deliver services while still maintaining our incredibly high dispensing volumes,” said Howells.

“After looking at a number of options, we opted for the FLOWRx solution by Centred Solutions as it provides us with one end-to-end solution and has the ability to handle our high volume of items.

“Moving to a hub and spoke model will allow us to grow the range of innovative services we are already delivering and ensure that our network of pharmacists and independent prescribers have the time they need to spend with patients.”

There are currently 13 pharmacies using the hub for their repeat original packs with more pharmacies joining in due course.

The hub is already dispensing an average of 45,000 packs a week – more than 80 per cent of packs requested by the branches.

Currently 13 Kamsons pharmacies are now using the hub for their repeat original packs as the hub ramps up. Throughout the course of the year the group will roll out this model of dispensing to a number of its pharmacies. Although it is early days the hub is already dispensing an average of 45,000 packs a week – more than 80% of packs requested by the branches. This leaves plenty of scope to ramp up quickly and fulfil items for other branches.

Ashley Kilgas, chief commercial officer at Centred Solutions, said: “For those considering this way of working, it is important to remember that hub and spoke is so much more than a system. It’s a significant change to the way pharmacies work.

“Our engineers are experts in hub and spoke workflows, data management, complex integration and governance.

“Our solutions team are trained pharmacists and pharmacy logistics experts who have spent many years working in a hub and spoke pharmacy environment before joining the team. Their experience in this area is unparalleled. They have been able to use that vast amount of knowledge and experience to guide the team at Kamsons through their hub and spoke journey.”

More For You

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less
Astrazeneca Office Building  Outlook

British Medical Journal has found data discrepancy during the crucial clinical trials of AstraZeneca's heart drug ticagrelor.

iStock

Top medics question trials of AstraZeneca's anti-clotting pill

The effectiveness of anti-clotting pill ticagrelor is now under a cloud, with some experts claiming that AstraZeneca misreported data when the trials were conducted more than a decade ago.

Sold as Brilinta, the pill was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack, and the generic versions of the drug are scheduled for this year.

Keep ReadingShow less